Register      Login
Sexual Health Sexual Health Society
Publishing on sexual health from the widest perspective
Shopping Cart: ( empty )
You are here: Home > Journals > SH > SH23088
RESEARCH ARTICLE (Open Access)
Contents Vol 20(3)

Impact of increased antiretroviral therapy use during the treatment as prevention era in Australia

Richard T. Gray https://orcid.org/0000-0002-2885-0483 A *
+ Author Affiliations
- Author Affiliations

A The Kirby Institute, UNSW Sydney, Sydney, NSW, Australia.

* Correspondence to: Rgray@kirby.unsw.edu.au

Handling Editor: Jason Ong

Sexual Health - https://doi.org/10.1071/SH23088
Submitted: 3 May 2023  Accepted: 2 June 2023   Published online: 3 July 2023

© 2023 The Author(s) (or their employer(s)). Published by CSIRO Publishing. This is an open access article distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND)

Abstract

Background: We analysed the impact of increased antiretroviral therapy (ART) on HIV epidemiology and healthcare costs in Australia during the ‘Treatment-as-prevention’ and ‘Undetectable equals Untransmissible (U=U)’ eras.

Methods: We conducted a retrospective modelling analysis between 2009 and 2019 to calculate the potential impact of early initiation of ART and treatment-as-prevention on HIV among gay and bisexual men (GBM). The model incorporates the change in the proportion diagnosed, treated, and virally suppressed, as well as the scale-up of oral HIV pre-exposure prophylaxis (PrEP) and the change in sexual behaviour during this period. We simulated a baseline and a no ART increase scenario and conducted a costing analysis from a national health provider perspective with cost estimates in 2019 AUD.

Results: Increasing ART use between 2009 and 2019 averted an additional 1624 [95% percentile interval (PI): 1220–2099] new HIV infections. Without the increase in ART, the number of GBM with HIV would have increased from 21 907 (95% PI: 20 753–23 019) to 23 219 (95% PI: 22 008–24 404) by 2019. HIV care and treatment costs for people with HIV increased by $296 (95% PI: $235–367) million AUD (assuming no change in annual healthcare costs). This was offset by a decrease in the lifetime HIV costs (with 3.5% discounting) for those newly infected of $458 (95% PI: $344–592) million AUD, giving a net cost saving of $162 (95%: $68–273) million AUD (and a benefits-to-cost ratio of 1.54).

Conclusions: Increasing the proportion of Australian GBM on effective ART between 2009 and 2019 likely resulted in substantial reductions in new HIV infections and cost savings.

Keywords: antiretroviral therapy, cost-effectiveness, epidemiology, HIV/AIDS, mathematical models, public health, treatment as prevention.


References

[1]  Bor J, Herbst AJ, Newell M-L, Barnighausen T. Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment. Science 2013; 339 961–5.
| Increases in adult life expectancy in rural South Africa: valuing the scale-up of HIV treatment.Crossref | GoogleScholarGoogle Scholar |

[2]  Brinkhof MWG, Boulle A, Weigel R, et al. Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality. PLoS Med 2009; 6 e1000066
| Mortality of HIV-infected patients starting antiretroviral therapy in sub-Saharan Africa: comparison with HIV-unrelated mortality.Crossref | GoogleScholarGoogle Scholar |

[3]  Egger M, May M, Chêne G, et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies. Lancet 2002; 360 119–29.
| Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies.Crossref | GoogleScholarGoogle Scholar |

[4]  May M, Boulle A, Phiri S, et al. Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes. Lancet 2010; 376 449–57.
| Prognosis of patients with HIV-1 infection starting antiretroviral therapy in sub-Saharan Africa: a collaborative analysis of scale-up programmes.Crossref | GoogleScholarGoogle Scholar |

[5]  Attia S, Egger M, Müller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS 2009; 23 1397–404.
| Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis.Crossref | GoogleScholarGoogle Scholar |

[6]  Donnell D, Baeten JM, Kiarie J, et al. Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis. Lancet 2010; 375 2092–8.
| Heterosexual HIV-1 transmission after initiation of antiretroviral therapy: a prospective cohort analysis.Crossref | GoogleScholarGoogle Scholar |

[7]  Cohen MS, Chen YQ, McCauley M, et al. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med 2011; 365 493–505.
| Prevention of HIV-1 infection with early antiretroviral therapy.Crossref | GoogleScholarGoogle Scholar |

[8]  Granich RM, Gilks CF, Dye C, De cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet 2009; 373 48–57.
| Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model.Crossref | GoogleScholarGoogle Scholar |

[9]  Wilson DP, Law MG, Grulich AE, Cooper DA, Kaldor JM. Relation between HIV viral load and infectiousness: a model-based analysis. Lancet 2008; 372 314–20.
| Relation between HIV viral load and infectiousness: a model-based analysis.Crossref | GoogleScholarGoogle Scholar |

[10]  The INSIGHT START Study Group Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med 2015; 373 795–807.
| Initiation of antiretroviral therapy in early asymptomatic HIV infection.Crossref | GoogleScholarGoogle Scholar |

[11]  The TEMPRANO ANRS 12136 Study Group A trial of early antiretrovirals and isoniazid preventive therapy in Africa. N Engl J Med 2015; 373 808–22.
| A trial of early antiretrovirals and isoniazid preventive therapy in Africa.Crossref | GoogleScholarGoogle Scholar |

[12]  Koenig SP, Dorvil N, Dévieux JG, et al. Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial. PLoS Med 2017; 14 e1002357
| Same-day HIV testing with initiation of antiretroviral therapy versus standard care for persons living with HIV: a randomized unblinded trial.Crossref | GoogleScholarGoogle Scholar |

[13]  Rosen S, Maskew M, Fox MP, et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial. PLoS Med 2016; 13 e1002015
| Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: the RapIT randomized controlled trial.Crossref | GoogleScholarGoogle Scholar |

[14]  Pilcher CD, Ospina-Norvell C, Dasgupta A, et al. The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a U.S. public health setting. J Acquir Immune Defic Syndr 2017; 74 44–51.
| The effect of same-day observed initiation of antiretroviral therapy on HIV viral load and treatment outcomes in a U.S. public health setting.Crossref | GoogleScholarGoogle Scholar |

[15]  The Lancet HIV U=U taking off in 2017. Lancet HIV 2017; 4 e475
| U=U taking off in 2017.Crossref | GoogleScholarGoogle Scholar |

[16]  UNAIDS. In danger: UNAIDS global AIDS update 2022. Geneva, Switzerland: Joint United Nations Programme on HIV/AIDS; 2022.

[17]  The Kirby Institute. HIV, viral hepatitis and sexually transmissible infections in Australia: annual surveillance report 2022. Sydney: Kirby Institute, UNSW Sydney; 2022.

[18]  UNAIDS. 90-90-90 – an ambitious treatment target to help end the AIDS epidemic. Joint United Nations Programme on HIV/AIDS (UNAIDS); 2014.

[19]  Granich R, Kahn JG, Bennett R, et al. Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050. PLoS ONE 2012; 7 e30216
| Expanding ART for treatment and prevention of HIV in South Africa: estimated cost and cost-effectiveness 2011–2050.Crossref | GoogleScholarGoogle Scholar |

[20]  Kahn JG, Marseille EA, Bennett R, Williams BG, Granich R. Cost-effectiveness of antiretroviral therapy for prevention. Curr HIV Res 2011; 9 405–15.
| Cost-effectiveness of antiretroviral therapy for prevention.Crossref | GoogleScholarGoogle Scholar |

[21]  Long LC, Maskew M, Brennan AT, et al. Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial. AIDS 2017; 31 1611–9.
| Initiating antiretroviral therapy for HIV at a patient’s first clinic visit: a cost-effectiveness analysis of the rapid initiation of treatment randomized controlled trial.Crossref | GoogleScholarGoogle Scholar |

[22]  Eaton JW, Menzies NA, Stover J, et al. Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models. Lancet Glob Health 2014; 2 e23–e34.
| Health benefits, costs, and cost-effectiveness of earlier eligibility for adult antiretroviral therapy and expanded treatment coverage: a combined analysis of 12 mathematical models.Crossref | GoogleScholarGoogle Scholar |

[23]  Jansson J, Kerr C, Wilson DP. Predicting the population impact of increased HIV testing and treatment in Australia. Sex Health 2014; 11 146–54.
| Predicting the population impact of increased HIV testing and treatment in Australia.Crossref | GoogleScholarGoogle Scholar |

[24]  Callander D, McManus H, Gray RT, et al. HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study. Lancet HIV 2023; 10 385–93.
| HIV treatment-as-prevention and its effect on incidence of HIV among cisgender gay, bisexual, and other men who have sex with men in Australia: a 10-year longitudinal cohort study.Crossref | GoogleScholarGoogle Scholar |

[25]  ASHM. Antiretroviral guidelines: US DHHS Guidelines with Australian commentary. ARV Guidelines. 2020. Available at https://arv.ashm.org.au/ [Accessed 5 April 2023]

[26]  Kelly SL, Wilson DP. HIV cascade monitoring and simple modeling reveal potential for reductions in HIV incidence. J Acquir Immune Defic Syndr 2015; 69 257–63.
| HIV cascade monitoring and simple modeling reveal potential for reductions in HIV incidence.Crossref | GoogleScholarGoogle Scholar |

[27]  Gray RT, Watson J, Cogle AJ, et al. Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive. Sex Health 2018; 15 13–9.
| Funding antiretroviral treatment for HIV-positive temporary residents in Australia prevents transmission and is inexpensive.Crossref | GoogleScholarGoogle Scholar |

[28]  Scott N, Stoové M, Kelly SL, Wilson DP, Hellard ME. Achieving 90-90-90 Human Immunodeficiency Virus (HIV) targets will not be enough to achieve the HIV incidence reduction target in Australia. Clin Infect Dis 2018; 66 1019–23.
| Achieving 90-90-90 Human Immunodeficiency Virus (HIV) targets will not be enough to achieve the HIV incidence reduction target in Australia.Crossref | GoogleScholarGoogle Scholar |

[29]  Holt M, Lea T, Mao L, et al. Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17. Lancet HIV 2018; 5 e448–e56.
| Community-level changes in condom use and uptake of HIV pre-exposure prophylaxis by gay and bisexual men in Melbourne and Sydney, Australia: results of repeated behavioural surveillance in 2013–17.Crossref | GoogleScholarGoogle Scholar |

[30]  Cohen MS, Chen YQ, McCauley M, et al. Antiretroviral therapy for the prevention of HIV-1 transmission. N Engl J Med 2016; 375 830–9.
| Antiretroviral therapy for the prevention of HIV-1 transmission.Crossref | GoogleScholarGoogle Scholar |

[31]  McCormack S, Dunn DT, Desai M, et al. Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial. Lancet 2016; 387 53–60.
| Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trial.Crossref | GoogleScholarGoogle Scholar |

[32]  Smith DK, Herbst JH, Zhang X, Rose CE. Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States. J Acquir Immune Defic Syndr 2015; 68 337–44.
| Condom effectiveness for HIV prevention by consistency of use among men who have sex with men in the United States.Crossref | GoogleScholarGoogle Scholar |

[33]  Lim M, Devine A, Gray RT, Kwon JA, Hutchinson JL, Ong JJ. Lifetime cost of HIV management in Australia: an economic model. Sex Health 2022; 19 517–24.
| Lifetime cost of HIV management in Australia: an economic model.Crossref | GoogleScholarGoogle Scholar |

[34]  Mao L, Broady T, Newman C, Treloar C, Holt M. Annual report of trends in behaviour 2022: HIV/STIs and sexual health in Australia. Sydney: UNSW; 2022. https://doi.org/10.26190/1fhh-ab12

[35]  The Kirby Institute, UNSW Sydney. The Australian HIV Observational database (AHOD). The Kirby Institute, UNSW Sydney; 2020. Available at https://kirby.unsw.edu.au/project/ahod [Accessed 26 April 2023]

[36]  Holt M, Lea T, Mao L, et al. Adapting behavioural surveillance to antiretroviral-based HIV prevention: reviewing and anticipating trends in the Australian Gay Community Periodic Surveys. Sex Health 2017; 14 72–9.
| Adapting behavioural surveillance to antiretroviral-based HIV prevention: reviewing and anticipating trends in the Australian Gay Community Periodic Surveys.Crossref | GoogleScholarGoogle Scholar |

[37]  Australian Bureau of Statistics. Consumer Price Index, Australia. 2023. Available at https://www.abs.gov.au/statistics/economy/price-indexes-and-inflation/consumer-price-index-australia/latest-release [Accessed 18 April 2023]

[38]  Gray RT, Neil Bretana P. leftygray/Cascade_calculations: version used for the 2022 Annual surveillance report HIV chapter; 2022. https://zenodo.org/record/7056070. Updated code available at https://github.com/The-Kirby-Institute/Cascade_calculations

[39]  Gray RT, Wilson David P, Guy Rebecca J, et al. Undiagnosed HIV infections among gay and bisexual men increasingly contribute to new infections in Australia. J Int AIDS Soc 2018; 21 e25104
| Undiagnosed HIV infections among gay and bisexual men increasingly contribute to new infections in Australia.Crossref | GoogleScholarGoogle Scholar |

[40]  Jansson J, Kerr CC, Mallitt K-A, Wu J, Gray RT, Wilson DP. Inferring HIV incidence from case surveillance with CD4+ cell counts. AIDS 2015; 29 1517–25.
| Inferring HIV incidence from case surveillance with CD4+ cell counts.Crossref | GoogleScholarGoogle Scholar |

[41]  Schneider K, Gray RT, Wilson DP. A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia. Clin Infect Dis 2014; 58 1027–34.
| A cost-effectiveness analysis of HIV preexposure prophylaxis for men who have sex with men in Australia.Crossref | GoogleScholarGoogle Scholar |

[42]  Australian Department of Health and Aged Care. (Pharmaceutical Benefits Scheme PBS) Recommendations made by the PBAC - December 2017. 2017. Available at https://www.pbs.gov.au/pbs/industry/listing/elements/pbac-meetings/pbac-outcomes/recommendations-pbac-december-2017 [Accessed 23 March 2022]

[43]  Australian Department of Health and Aged Care. Pharmaceutical Benefits Scheme (PBS) Australian Statistics on Medicines. 2016. Available at https://www.pbs.gov.au/info/statistics/asm/australian-statistics-on-medicines [Accessed 17 April 2023]

[44]  Gray RT. Impact and effectiveness of U=U on HIV in Australia. The-Kirby-Institute/Impact_TasP_Australia. Zenodo; 2023. 10.5281/zenodo.7865576. Updated code available at: https://github.com/The-Kirby-Institute/Impact_TasP_Australia

[45]  Bares SH, Scarsi KK. A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV. Curr Opin HIV AIDS 2022; 17 22–31.
| A new paradigm for antiretroviral delivery: long-acting cabotegravir and rilpivirine for the treatment and prevention of HIV.Crossref | GoogleScholarGoogle Scholar |